Study Evaluating SC262 in Subjects With r/r Non-Hodgkin's Lymphoma (VIVID)
Status:
RECRUITING
Trial end date:
2029-03-01
Target enrollment:
Participant gender:
Summary
SC262-101 is a Phase 1 study to evaluate SC262 safety and tolerability, anti-tumor activity, cellular kinetics, immunogenicity, and exploratory biomarkers.